Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Socrates E Papapoulos

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
The Journal of Experimental Medicine|March 17, 2004
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonistRutger L van Bezooijen, Bernard A J Roelen, Annemieke Visser, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 13, 2006
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formationRutger L van Bezooijen, J Peter Svensson, Daniël Eefting, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 11, 2002
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extensionCaroline Brumsen, Socrates E Papapoulos, Paul Lips, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|December 30, 2006
SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular developmentRutger L van Bezooijen, Marco C Deruiter, Nathalie Vilain, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|August 4, 2011
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practiceDidier B Hans, John A Kanis, Sanford Baim, et al.
Journal of Medicinal Chemistry|April 15, 2005
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorptionJohn M Sanders, Yongcheng Song, Julian M W Chan, et al.
The American Journal of Pathology|August 29, 2007
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivoJeroen T Buijs, Cyrill A Rentsch, Geertje van der Horst, et al.
Cancer Research|September 19, 2007
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancerJeroen T Buijs, Nico V Henriquez, Petra G M van Overveld, et al.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
The Journal of Experimental Medicine|March 17, 2004
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonistRutger L van Bezooijen, Bernard A J Roelen, Annemieke Visser, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 13, 2006
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formationRutger L van Bezooijen, J Peter Svensson, Daniël Eefting, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 11, 2002
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extensionCaroline Brumsen, Socrates E Papapoulos, Paul Lips, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|December 30, 2006
SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular developmentRutger L van Bezooijen, Marco C Deruiter, Nathalie Vilain, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|August 4, 2011
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practiceDidier B Hans, John A Kanis, Sanford Baim, et al.
Journal of Medicinal Chemistry|April 15, 2005
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorptionJohn M Sanders, Yongcheng Song, Julian M W Chan, et al.
The American Journal of Pathology|August 29, 2007
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivoJeroen T Buijs, Cyrill A Rentsch, Geertje van der Horst, et al.
Cancer Research|September 19, 2007
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancerJeroen T Buijs, Nico V Henriquez, Petra G M van Overveld, et al.
The Lancet. Diabetes & Endocrinology|November 3, 2019
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, et al.
Pageof 8